Loading
Loading
Research Overview
Khavinson tripeptide targeted at cartilage and connective tissue; proposed to stimulate chondrocyte proliferation and cartilage matrix synthesis, with studies suggesting reduced cartilage degradation markers in ageing models.
Cartalax is a short, cartilage-specific peptide bioregulator investigated in experimental research for its role in regulating gene expression and cellular homeostasis in cartilage tissue. Structurally defined as the tripeptide Ala–Glu–Asp (AED), Cartalax was originally identified through peptide fractionation of animal cartilage extracts and is classified within a family of organ-specific cytomedins. These peptides are characterized by their small size and their reported capacity to influence transcriptional activity in cells derived from their tissue of origin.
Preclinical studies conducted in cell cultures, cartilage explants, and animal models suggest that Cartalax can enter chondrocytes and interact with intracellular regulatory systems associated with extracellular matrix maintenance, cellular stress adaptation, and age-related molecular changes. In vitro experiments have reported associations between Cartalax exposure and increased expression of cartilage matrix components, including collagen and proteoglycans, alongside reduced expression of matrix-degrading enzymes under inflammatory or oxidative stress conditions. Additional findings indicate modulation of senescence-associated markers and altered cytokine signaling profiles in aging cartilage cell models.In animal models of cartilage injury and degeneration, peptide preparations containing Cartalax have been associated with preserved cartilage architecture, reduced histological damage scores, and improved biomechanical properties of joint cartilage when compared with untreated controls. These observations are supported by mechanistic studies suggesting involvement of transcriptional and epigenetic pathways, including regulation of sirtuin signaling, oxidative stress responses, and apoptosis-related factors.All findings related to Cartalax are derived exclusively from preclinical research. No human studies have been conducted, and its safety profile, pharmacokinetics, and translational relevance remain uncharacterized. Cartalax is therefore regarded solely as an experimental research tool for studying cartilage biology and tissue-specific peptide regulation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, cartalax has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Cartalax research is most relevant to protocols examining:
Cartilage repair and chondrocyte biology research
Osteoarthritis model and cartilage degradation studies
Connective tissue matrix synthesis investigations
Researchers studying organ-targeted bioregulators for joint health
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Khavinson tripeptide targeted at cartilage and connective tissue; proposed to stimulate chondrocyte proliferation and cartilage matrix synthesis, with studies suggesting reduced cartilage degradation markers in ageing models.
| Parameter | Value |
|---|---|
| Dose range | 10–20 mg/day (cycled) |
| Schedule | Daily (cycled) |
| Route | Subcutaneous |
| Half-life | ~Hours |
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.